Viracta Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Mark Rothera

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage	40.5%
CEO tenure	1.8yrs
CEO ownership	n/a
Management average tenure	2.6yrs
Board average tenure	3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Mark Rothera's remuneration changed compared to Viracta Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$48m
Dec 31 2023	US$1m	US$590k	-US$51m
Sep 30 2023	n/a	n/a	-US$48m
Jun 30 2023	n/a	n/a	-US$53m
Mar 31 2023	n/a	n/a	-US$51m
Dec 31 2022	US$6m	US$167k	-US$49m

Compensation vs Market: Mark's total compensation ($USD1.46M) is above average for companies of similar size in the German market ($USD419.73K).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

CEO

Mark Rothera (61 yo)

1.8yrs

Tenure

US$1,456,596

Compensation

Mr. Mark Andrew Rothera serves as Chief Executive Officer, President & Director of Viracta Therapeutics, Inc. since September 19, 2022. He served as President, Chief Executive Officer and Executive Directo...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Mark Rothera	CEO, President & Director	1.8yrs	US$1.46m	no data
Darrel Cohen	Chief Medical Officer	less than a year	US$1.05m	0% $ 0
Susan Perrine	Scientific Founder and Consultant	13.5yrs	no data	no data
Ronald Berenson	Co-Founder and Consultant	13.5yrs	no data	no data
George Hillman	Co-Founder	no data	no data	no data
Thalia Papayannopoulou	Co-Founder	no data	no data	no data
Robert Williams	Co-Founder	no data	no data	no data
Douglas Faller	Scientific Founder & Chairman of Scientific Advisory Board	no data	no data	no data
Michael Faerm	Chief Financial Officer	less than a year	no data	no data
Ayman El-Guindy	Chief Scientific Officer	2.9yrs	no data	no data
Stewart Brown	Senior VP of Legal Affairs & General Counsel	2.3yrs	no data	no data
Cheryl Madsen	Senior Vice President of Regulatory Affairs	3.3yrs	no data	no data

2.6yrs

Average Tenure

61yo

Average Age

Experienced Management: RYI's management team is considered experienced (2.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Mark Rothera	CEO, President & Director	1.8yrs	US$1.46m	no data
Douglas Faller	Scientific Founder & Chairman of Scientific Advisory Board	no data	no data	no data
Ivor Royston	Director	3.3yrs	US$90.76k	2.06% $ 508.6k
Thomas Darcy	Independent Director	3.3yrs	US$113.26k	0% $ 0
Ronald Levy	Member of Scientific Advisory Board	5.8yrs	no data	no data
Carl June	Member of Scientific Advisory Board	5.8yrs	no data	no data
Barry Simon	Independent Director	3.3yrs	US$110.76k	0% $ 0
Roger Pomerantz	Independent Chairman of the Board	3.3yrs	US$210.27k	0.28% $ 68.2k
Lawrence Young	Member of Scientific Advisory Board	5.8yrs	no data	no data
Robert Baiocchi	Member of Scientific Advisory Board	5.8yrs	no data	no data
Pierluigi Porcu	Member of Scientific Advisory Board	5.8yrs	no data	no data
Stephen Rubino	Independent Director	3.3yrs	US$108.26k	0% $ 0

3.3yrs

Average Tenure

67yo

Average Age

Experienced Board: RYI's board of directors are considered experienced (3.3 years average tenure).

Viracta Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

High number of new directors

High number of new directors

Recent updates

Viracta Therapeutics Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing under Nasdaq Listing Rule 5450(a)(1)

Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Insufficient new directors

Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial

New major risk - Revenue and earnings growth

Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan

New major risk - Revenue and earnings growth

Viracta Therapeutics, Inc. Provides Clinical Update

Viracta Therapeutics Announces Interim Data from Phase 1B/2 Clinical Trial of Nana-Val in Patients with Epstein-Barr Virus-Positive Solid Tumors That Show Confirms Tumor Responses At Higher Dose Levels

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

Viracta Therapeutics, Inc. Receives A Written Notice from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market LLC

Viracta Therapeutics, Inc. Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer

Viracta Therapeutics’ Pivotal Naval-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Viracta Therapeutics, Inc. Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

Viracta Therapeutics, Inc. Announces Preliminary Dose-Ranging Data from the Phase 1B/2 Trial of Nana-Val in Patients

High number of new directors

High number of new directors

High number of new directors

Viracta Therapeutics, Inc. Announces CEO Changes

Viracta Therapeutics, Inc. Announces Resignation of Michael Huang as Director

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

Viracta Therapeutics, Inc.(NasdaqGS:VIRX) dropped from Russell 2500 Value Index

Viracta Therapeutics, Inc. Provides an Update on the Phase 1b/2 Trial of Nana-Val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Less than half of directors are independent

Viracta Therapeutics, Inc. Announces That Gur Roshwalb Will Not Stand for Re-Election At the Company’s 2022 Annual Meeting of Stockholders

Viracta Therapeutics Announces First Patient Dosed in Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive Solid Tumors

Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021

Viracta Therapeutics Announces FDA Clearance of IND Application for Phase 1b/2 Trial in Epstein-Barr Virus-Positive (EBV+) Solid Tumors

Viracta Therapeutics, Inc. Announces the Initiation of Naval-1, A Global Pivotal Trial for the Treatment of Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma

Viracta Therapeutics, Inc. Announces Executive Changes

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age